vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and INVESTORS TITLE CO (ITIC). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $69.5M, roughly 1.2× INVESTORS TITLE CO). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 14.0%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
IOVA vs ITIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $69.5M |
| Net Profit | — | — |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 13.8% |
| Net Margin | — | — |
| Revenue YoY | 17.7% | -1.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $3.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $69.5M | ||
| Q3 25 | $67.5M | $73.0M | ||
| Q2 25 | $60.0M | $73.6M | ||
| Q1 25 | $49.3M | $56.6M | ||
| Q4 24 | $73.7M | $70.6M | ||
| Q3 24 | $58.6M | $68.8M | ||
| Q2 24 | $31.1M | $65.4M | ||
| Q1 24 | $715.0K | $53.5M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $12.2M | ||
| Q2 25 | $-111.7M | $12.3M | ||
| Q1 25 | $-116.2M | $3.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $9.3M | ||
| Q2 24 | $-97.1M | $8.9M | ||
| Q1 24 | $-113.0M | $4.5M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 13.8% | ||
| Q3 25 | -140.7% | 20.7% | ||
| Q2 25 | -189.8% | 21.5% | ||
| Q1 25 | -245.8% | 7.2% | ||
| Q4 24 | -117.5% | 15.3% | ||
| Q3 24 | -152.1% | 16.8% | ||
| Q2 24 | -327.6% | 17.2% | ||
| Q1 24 | -16464.6% | 10.8% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | 16.7% | ||
| Q2 25 | -186.2% | 16.7% | ||
| Q1 25 | -235.5% | 5.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | 13.5% | ||
| Q2 24 | -312.2% | 13.6% | ||
| Q1 24 | -15800.8% | 8.5% |
| Q4 25 | — | $3.97 | ||
| Q3 25 | — | $6.45 | ||
| Q2 25 | $-0.33 | $6.48 | ||
| Q1 25 | $-0.36 | $1.67 | ||
| Q4 24 | $-0.24 | $4.41 | ||
| Q3 24 | $-0.28 | $4.92 | ||
| Q2 24 | $-0.34 | $4.70 | ||
| Q1 24 | $-0.42 | $2.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $89.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $268.3M |
| Total Assets | $913.2M | $363.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $89.6M | ||
| Q3 25 | $300.8M | $110.8M | ||
| Q2 25 | $301.2M | $90.1M | ||
| Q1 25 | $359.7M | $81.7M | ||
| Q4 24 | $323.8M | $83.8M | ||
| Q3 24 | $397.5M | $112.9M | ||
| Q2 24 | $412.5M | $111.2M | ||
| Q1 24 | $356.2M | $135.0M |
| Q4 25 | $698.6M | $268.3M | ||
| Q3 25 | $702.3M | $278.0M | ||
| Q2 25 | $698.5M | $266.2M | ||
| Q1 25 | $767.9M | $254.4M | ||
| Q4 24 | $710.4M | $251.8M | ||
| Q3 24 | $773.5M | $271.3M | ||
| Q2 24 | $768.5M | $261.8M | ||
| Q1 24 | $680.0M | $254.0M |
| Q4 25 | $913.2M | $363.1M | ||
| Q3 25 | $904.9M | $363.3M | ||
| Q2 25 | $907.4M | $345.8M | ||
| Q1 25 | $966.7M | $333.8M | ||
| Q4 24 | $910.4M | $333.6M | ||
| Q3 24 | $991.1M | $352.0M | ||
| Q2 24 | $964.3M | $340.3M | ||
| Q1 24 | $869.8M | $329.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $30.9M |
| Free Cash FlowOCF − Capex | $-61.9M | $25.4M |
| FCF MarginFCF / Revenue | -71.3% | 36.5% |
| Capex IntensityCapex / Revenue | 10.7% | 8.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $47.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $30.9M | ||
| Q3 25 | $-78.7M | $17.2M | ||
| Q2 25 | $-67.4M | $8.9M | ||
| Q1 25 | $-103.7M | $-75.0K | ||
| Q4 24 | $-73.3M | $29.8M | ||
| Q3 24 | $-59.0M | $7.8M | ||
| Q2 24 | $-98.4M | $8.4M | ||
| Q1 24 | $-122.3M | $1.4M |
| Q4 25 | $-61.9M | $25.4M | ||
| Q3 25 | $-89.5M | $15.8M | ||
| Q2 25 | $-74.9M | $7.3M | ||
| Q1 25 | $-109.9M | $-1.4M | ||
| Q4 24 | $-77.5M | $22.4M | ||
| Q3 24 | $-61.3M | $6.1M | ||
| Q2 24 | $-98.9M | $6.3M | ||
| Q1 24 | $-126.5M | $-793.0K |
| Q4 25 | -71.3% | 36.5% | ||
| Q3 25 | -132.7% | 21.7% | ||
| Q2 25 | -124.9% | 9.9% | ||
| Q1 25 | -222.8% | -2.5% | ||
| Q4 24 | -105.1% | 31.7% | ||
| Q3 24 | -104.6% | 8.8% | ||
| Q2 24 | -317.9% | 9.7% | ||
| Q1 24 | -17685.3% | -1.5% |
| Q4 25 | 10.7% | 8.0% | ||
| Q3 25 | 16.1% | 1.8% | ||
| Q2 25 | 12.4% | 2.1% | ||
| Q1 25 | 12.6% | 2.4% | ||
| Q4 24 | 5.7% | 10.5% | ||
| Q3 24 | 3.9% | 2.5% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 583.4% | 4.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | — | 0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
ITIC
Segment breakdown not available.
